Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Long-Term Deferred Tax (2018 - 2024)

Abvc Biopharma (ABVC) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $6.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Deferred Tax rose 5263.86% year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Dec 2023, up 5263.86%, and an annual FY2023 reading of $6.3 million, up 5263.86% over the prior year.
  • Long-Term Deferred Tax was $6.3 million for Q4 2023 at Abvc Biopharma, up from $34256.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $6.3 million in Q4 2023 and bottomed at $34256.0 in Q3 2023.
  • Average Long-Term Deferred Tax over 5 years is $1.4 million, with a median of $1.4 million recorded in 2019.
  • Peak annual rise in Long-Term Deferred Tax hit 5263.86% in 2023, while the deepest fall reached 96.72% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $1.5 million in 2019, then increased by 22.64% to $1.8 million in 2020, then crashed by 45.16% to $981912.0 in 2021, then plummeted by 88.07% to $117110.0 in 2022, then surged by 5263.86% to $6.3 million in 2023.
  • Business Quant data shows Long-Term Deferred Tax for ABVC at $6.3 million in Q4 2023, $34256.0 in Q3 2023, and $35472.0 in Q2 2023.